At the time, the BCR-ABL tyrosine kinase was the best-credentialed tyrosine kinase target in oncology. A couple of years earlier, I had advised Nick that CML, driven by BCR-ABL kinase activity ...
Hosted on MSN1y
Terns scores FDA orphan designation for CML therapyTERN-701 is an oral allosteric BCR-ABL tyrosine kinase inhibitor (TKI) and is one of the two therapies that Terns plans to focus its resources on this year. The treatment is being evaluated in a ...
5, 6 Given the requirement for dimerization for kinase activation, it is conceivable that the deletion mutants have a dominant-negative effect on the native BCR-ABL by formation of heterodimers ...
Hosted on MSN11mon
Sun Pharma abandons Parkinson's drug trialThe study was designed to evaluate the safety and efficacy of the selective c-Abl tyrosine kinase inhibitor in patients with early Parkinson's disease. The PROSEEK study was a global trial that ...
Sino-American biopharma Ascentage Pharma has announced that olverembatinib has been granted Breakthrough Therapy Designation ...
It also focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain as ...
By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results